Lataa...
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
AIM: Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmac...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7591087/ https://ncbi.nlm.nih.gov/pubmed/33122892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S275336 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|